Enliven Therapeutics (ELVN) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Enliven Therapeutics (ELVN) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Enliven Therapeutics

· ELVN

Dashboard

Financials

Ratios

Valuation

Statistics

3.359 B

+0.81%

General

Market Cap: $3.36B
Enterprise Value: $3.17B
Shares Outstanding: 69,820,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: —
Operating Margin: —
Net Profit Margin: —
FCF Margin: —
ROA: -11.64%
ROE: -18.55%
ROIC: -13.88%
Current Ratio: 64.07
Debt-to-Equity: 0.00
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: —
P/FCF: —
P/B: 3.69
EV/EBITDA: -29.93

Growth

Rev 1Y: —
Rev 1Y Fwd Est: —
Rev 3Y (CAGR): —
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR): —
EPS 10Y (CAGR): —

Income Statement (TTM)

Revenue: —
Gross Margin: —
Operating Expenses: $124.37M
Operating Income: -$124.41M
Net Profit: -$105.93M

Balance Sheet

Cash and Equivalents: $135.51M
Working Capital: $893.18M
Total Assets: $910.22M
Net Debt: -$134M
Total Liabilities: $15.07M
Total Equity: $895.15M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$66.94M
Cash Flow from Investing: -$390.72M
Cash Flow from Financing: $473.73M
Free Cash Flow: -$67.04M
Capital Expenditures: $98K